Humanigen Inc. (HGEN) Prices 5M Share Common Offering at $18.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Humanigen Inc. (HGEN) Announces Proposed Public Offering of 5M Shares of Common Stock
March 29, 2021 4:11 PM EDTHumanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock. In connection with this... More
Pre-Open Stock Movers 03/29: (HGEN) (FLY) (HMHC) Higher; (ORPH) (NMR) (CS) Lower (more...)
March 29, 2021 9:29 AM EDTToday's Pre-Open Stock Movers:
Humanigen, Inc. (Nasdaq: HGEN) 65.3% HIGHER; announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.
Humanigen Inc. (HGEN) Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
March 29, 2021 7:06 AM EDTHumanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.
The results from our Phase 3 clinical... More
